A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Dureja, Harish
- Formulation and Characterization of Gastroretentive Floating Tablets of Atorvastatin Calcium Using Central Composite Design
Authors
1 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak – 124001, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 3 (2017), Pagination: 247-256Abstract
The aim of the study was to develop a gastroretentive floating drug delivery system of atorvastatin calcium by effervescence technique.
Design/methodology/approach: The objective behind the study was to investigate the effect of concentration of HPMC K4M (X), concentration of guar gum (X), concentration of sodium bicarbonate (X) on the release of 1 2 3 atorvastatin calcium using central composite design.The floating tablets were formulated using atorvastatin calcium (20% w/w), HPMC K4M (5-15% w/w), guar gum (5-15% w/w), sodium bicarbonate (4-12% w/w), lactose (q.s.), talc (2% w/w) and magnesium stearate (1% w/w). Atorvastatin calcium floating tablets were evaluated for physical characterization viz. hardness, swelling index, floating capacity, weight variation, friability, in vitro drug release and kinetic studies.
Findings: All tablets were floated for more than 12 hrs in 0.1 N HCl at 37±0.5°C and the in vitro drug release was found to be vary from 79% to 93%. The percentage cumulative drug released was maximum at low value of HPMC, low value of guar gum and high value of sodium bicarbonate. A mathematical model was developed to formulate floating tablets of atorvastatin calcium. The data fitting to Korsemeyer-Peppas equation revealed that the release mechanism from the dosage form followed the non-fickian transport.
Value: The gastroretentive floating tablets of atorvastatin calcium will enhance the patient compliance and play a vital role in improving patient's quality of life.
Keywords
Atorvastatin Calcium, Central Composite Design, In Vitro Drug Release, Floating Tablets.Full Text
References
- Chuch H, Zia H, Rhodes C. Development of oral drug delivery system using floating microspheres. Drug Development and Industrial Pharmacy. 1995; 2(1): 1725-35.
- Bansal AK, Chawla G, Gupta P, Koradia V. Gastroretention: A means to address regional variability in intestinal absorption. Pharmaceutical Technology. 2003;2(1):50-68.
- Sharma N, Agarwal D, Gupta MK, Khinchi M. A comprehensive review on floating drug delivery system. International Journal of Research and Pharmaceutical Biomedical Sciences. 2011; 2(2): 428-41.
- Kumar M, Pandey P, Dureja H. Box-Behnken designed gastroretentive floating tablets of famotidine. Drug Development and Delivery. 2015; 15(3): 62-7.
- Elmowafy EM, Awad GA, Mansour S, El-Shamy AE. Release mechanisms behind polysaccharides-based famotidine controlled release matrix tablets. AAPS PharmSciTech. 2008; 9(4): 1230-9.
- Baumgartner S, Kristle J, Vrecer F, Vodopivec P, Zorko B. Optimization of floating matrix tablets and evaluation of their gastric residence time. International Journal of Pharmaceutics. 2000; 195:125-35.
- Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. Oral sustained delivery of atenolol from floating matrix tablets - formulation and in vitro evaluation. Drug Development and Industrial Pharmacy. 2005; 31: 367-74.
- Shahiwala A. Statistical optimization of Ranitidine HCl floating pulsatile delivery system for chromotherapy of nocturnal acid breakthrough. European Journal of Pharmaceutical Sciences. 2009; 37: 363-9.
- Timmermans J, Moes AJ. How well do floating dosage forms float? International Journal of Pharmaceutics. 1990; 62: 207-11.
- Chordiya M, Gangurde H, Borkar V. Technologies, optimization and analytical parameters in gastroretentive drug delivery systems. Current Sciences. 2017; 112(5): 946-53.